Targets › ELN
1 program from 1 company in 1 trial: 1 Phase 1; Other.
Major structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely. Molecular determinant of the late arterial morphogenesis, stabilizing arterial structure by regulating proliferation and organization of vascular smooth muscle (By similarity). (UniProt, P15502)
Open in Phaseline: the race on ELN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Krystal Biotech | KB304 HSV-1 vector delivering human collagen (COL3) and elastin (tropoelastin) genes | COL3, ELN | Phase 1 | Wrinkles in Decolletage | – |
Wrinkles in Decolletage (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.